drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T-cell)
drug_description
Autologous CD19-directed CAR T-cell therapy with CD28 costimulation; gene-modified T cells recognize CD19 on malignant B cells to drive T-cell activation and cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
axicabtagene ciloleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-directed chimeric antigen receptor with CD28 costimulation. Upon binding CD19 on malignant B cells, CAR signaling activates and expands the T cells, triggering perforin/granzyme-mediated cytotoxicity and cytokine release to eliminate CD19+ B cells.
drug_name
Axicabtagene ciloleucel (Axi-cel)
nct_id_drug_ref
NCT06213311